Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.55 HKD | -0.92% | +8.40% | +5.38% |
Apr. 26 | Central Bank, Tech Outlooks Lift Major Asian Stock Markets | MT |
Apr. 16 | Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The stock, which is currently worth 2024 to 0.11 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.38% | 8.59B | C | ||
+17.35% | 71.39B | C+ | ||
+2.39% | 25.1B | C+ | ||
+6.69% | 8.19B | B | ||
-20.96% | 7.91B | B- | ||
+0.49% | 4.54B | B- | ||
+17.12% | 4.31B | B+ | ||
-3.38% | 3.93B | B- | ||
-2.61% | 3.86B | B | ||
+22.08% | 3.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1099 Stock
- Ratings Sinopharm Group Co. Ltd.